Gelesis Holdings, Inc. (NYSE:GLS – Get Rating) was the target of a large growth in short interest during the month of December. As of December 30th, there was short interest totalling 637,300 shares, a growth of 16.0% from the December 15th total of 549,200 shares. Approximately 3.1% of the company's stock are short sold. Based on an average daily trading volume, of 148,700 shares, the days-to-cover ratio is presently 4.3 days.
Insider Activity at Gelesis
In related news, Director Raju S. Kucherlapati purchased 92,000 shares of the stock in a transaction that occurred on Monday, November 21st. The stock was acquired at an average cost of $0.45 per share, with a total value of $41,400.00. Following the transaction, the director now owns 190,264 shares of the company's stock, valued at approximately $85,618.80. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 11.90% of the stock is currently owned by insiders.
Get Gelesis alerts:Institutional Inflows and Outflows
Institutional investors have recently bought and sold shares of the business. Vanguard Group Inc. grew its stake in shares of Gelesis by 564.9% during the 3rd quarter. Vanguard Group Inc. now owns 2,935,975 shares of the company's stock worth $3,171,000 after acquiring an additional 2,494,379 shares during the period. Vitruvian Partners LLP bought a new position in shares of Gelesis during the 3rd quarter worth $2,026,000. Neuberger Berman Group LLC bought a new position in shares of Gelesis during the 1st quarter worth $5,276,000. BlackRock Inc. grew its stake in shares of Gelesis by 33.5% during the 3rd quarter. BlackRock Inc. now owns 774,052 shares of the company's stock worth $835,000 after acquiring an additional 194,043 shares during the period. Finally, Northeast Financial Consultants Inc grew its stake in shares of Gelesis by 1,480.1% during the 3rd quarter. Northeast Financial Consultants Inc now owns 395,035 shares of the company's stock worth $427,000 after acquiring an additional 370,035 shares during the period. Institutional investors own 16.71% of the company's stock.
Gelesis Price Performance
NYSE GLS traded up $0.05 on Friday, reaching $0.37. The company had a trading volume of 63,333 shares, compared to its average volume of 148,494. The company has a current ratio of 0.69, a quick ratio of 0.45 and a debt-to-equity ratio of 5.89. The company's fifty day moving average is $0.35 and its 200 day moving average is $0.84. Gelesis has a 52-week low of $0.22 and a 52-week high of $6.76.Gelesis (NYSE:GLS – Get Rating) last announced its quarterly earnings data on Monday, November 14th. The company reported ($0.20) earnings per share (EPS) for the quarter. The business had revenue of $6.65 million during the quarter.
About Gelesis
(Get Rating)
Gelesis Holdings Inc, a commercial stage biotherapeutics company, developing a biomimicry to treat the genesis of obesity and GI-related chronic diseases. The company also provides PLENITY, an orally administered, non-stimulant, and non-systemic aid for weight management. In addition, it offers a product for obesity and overweight and a pipeline with potential therapies for non-alcoholic fatty liver disease/non-alcoholic steatohepatitis, type 2 diabetes, and GS500 for Functional Constipation.
Featured Articles
- Get a free copy of the StockNews.com research report on Gelesis (GLS)
- MarketBeat Week in Review – 1/16 – 1/20
- Does Old Dominion Show That Trucking Is Hitting The Brakes?
- Nordstrom Puts Fear Of Markdowns Into Retail Sector
- Exxon Mobil Stock: Within Striking Distance Of Buy Point
- High-Dividend-Yielding BHP Sees China Driving '23 Growth
Receive News & Ratings for Gelesis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gelesis and related companies with MarketBeat.com's FREE daily email newsletter.